Cargando…
Evaluation of (64)Cu-Based Radiopharmaceuticals that Target Aβ Peptide Aggregates as Diagnostic Tools for Alzheimer’s Disease
[Image: see text] Positron emission tomography (PET) imaging agents that detect amyloid plaques containing amyloid beta (Aβ) peptide aggregates in the brain of Alzheimer’s disease (AD) patients have been successfully developed and recently approved by the FDA for clinical use. However, the short hal...
Autores principales: | Bandara, Nilantha, Sharma, Anuj K., Krieger, Stephanie, Schultz, Jason W., Han, Byung Hee, Rogers, Buck E., Mirica, Liviu M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2017
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5677763/ https://www.ncbi.nlm.nih.gov/pubmed/28823165 http://dx.doi.org/10.1021/jacs.7b05937 |
Ejemplares similares
-
Metal-chelating benzothiazole multifunctional compounds for the modulation and (64)Cu PET imaging of Aβ aggregation
por: Huang, Yiran, et al.
Publicado: (2020) -
Coordination Chemistry of Bifunctional Chemical Agents
Designed for Applications in (64)Cu PET Imaging for Alzheimer’s
Disease
por: Sharma, Anuj K., et al.
Publicado: (2017) -
(64)Cu-based Radiopharmaceuticals in Molecular Imaging
por: Zhou, Yeye, et al.
Publicado: (2019) -
Turn-on fluorescent sensors for Cu-rich amyloid β peptide aggregates
por: Huang, Yiran, et al.
Publicado: (2022) -
Recent Advances in (64)Cu/(67)Cu-Based Radiopharmaceuticals
por: Krasnovskaya, Olga O., et al.
Publicado: (2023)